{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:27:44Z","timestamp":1782563264055,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) is a severely debilitating condition which markedly restricts activity and function of affected people. Since the beginning of the COVID-19 pandemic ME\/CFS related to post-acute COVID-19 syndrome (PACS) can be diagnosed in a subset of patients presenting with persistent fatigue 6 months after a mostly mild SARS-CoV-2 infection by fulfillment of the Canadian Consensus Criteria (CCC 2003). Induction of autoimmunity after viral infection is a mechanism under intensive investigation. In patients with ME\/CFS, autoantibodies against thyreoperoxidase (TPO), beta-adrenergic receptors (\u00df2AR), and muscarinic acetylcholine receptors (MAR) are frequently found, and there is evidence for effectiveness of immunomodulation with B cell depleting therapy, cyclophosphamide, or intravenous immunoglobulins (IVIG). Preliminary studies on the treatment of ME\/CFS patients with immunoadsorption (IA), an apheresis that removes antibodies from plasma, suggest clinical improvement. However, evidence from placebo-controlled trials is currently missing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this double-blinded, randomized, sham-controlled, exploratory trial the therapeutic effect of five cycles of IA every other day in patients with ME\/CFS, including patients with post-acute COVID-19 chronic fatigue syndrome (PACS-CFS), will be evaluated using the validated Chalder Fatigue Scale, a patient-reported outcome measurement. A total of 66 patients will be randomized at a 2:1 ratio: 44 patients will receive IA (active treatment group) and 22 patients will receive a sham apheresis (control group). Moreover, safety, tolerability, and the effect of IA on patient-reported outcome parameters, biomarker-related objectives, cognitive outcome measurements, and physical parameters will be assessed. Patients will be hospitalized at the clinical site from day 1 to day 10 to receive five IA treatments and medical visits. Four follow-up visits (including two visits at site and two visits via telephone call) at month 1 (day 30), 2 (day 60), 4 (day 120), and 6 (day 180; EOS, end of study visit) will take place.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Although ME\/CFS including PACS-CFS causes an immense individual, social, and economic burden, we lack efficient therapeutic options. The present study aims to investigate the efficacy of immunoadsorption and to contribute to the etiological understanding and establishment of diagnostic tools for ME\/CFS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Registration Number: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05710770\">NCT05710770<\/jats:ext-link>. Registered on 02 February 2023.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-024-07982-5","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T11:06:15Z","timestamp":1709809575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["IA-PACS-CFS: a double-blinded, randomized, sham-controlled, exploratory trial of immunoadsorption in patients with chronic fatigue syndrome (CFS) including patients with post-acute COVID-19 CFS (PACS-CFS)"],"prefix":"10.1186","volume":"25","author":[{"given":"Hannah","family":"Pre\u00dfler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0969-4120","authenticated-orcid":false,"given":"Marie-Luise","family":"Machule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Ufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"B\u00fcnger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie Yuanting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Beraha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthes","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susen","family":"Burock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bruckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiana","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Wilck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Reshetnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Uwe","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Endres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Pr\u00fcss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"issue":"1","key":"7982_CR1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12967-020-02269-0","volume":"18","author":"EJ Lim","year":"2020","unstructured":"Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome\/myalgic encephalomyelitis (CFS\/ME). J Transl Med. 2020;18(1):100.","journal-title":"J Transl Med."},{"issue":"6","key":"7982_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jama.2020.12603","volume":"324","author":"A Carfi","year":"2020","unstructured":"Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603\u20135.","journal-title":"JAMA."},{"key":"7982_CR3","volume-title":"Characterizing long COVID in an international cohort: 7 months of symptoms and their impact","author":"GSA Davis","year":"2020","unstructured":"Davis GSA, McCorkell L, Wei H, Low RJ, Re\u2019em Y, Redfield S, Austin JP, Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. medRxiv; 2020."},{"issue":"9","key":"7982_CR4","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/infdis\/jiac136","volume":"226","author":"C Chen","year":"2022","unstructured":"Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226(9):1593\u2013607.","journal-title":"J Infect Dis."},{"issue":"4","key":"7982_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1365-2796.2011.02428.x","volume":"270","author":"BM Carruthers","year":"2011","unstructured":"Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med. 2011;270(4):327\u201338.","journal-title":"J Intern Med."},{"key":"7982_CR6","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.06.21249256","volume-title":"Chronic COVID-19 syndrome and chronic fatigue syndrome (ME\/CFS) following the first pandemic wave in Germany- a first analysis of a prospective observational study","author":"C Kedor","year":"2021","unstructured":"Kedor C, Freitag H, Meyer-Arndt L, Wittke K, Zoller T, Steinbeis F, Haffke M, Rudolf G, Heidecker B, Volk HD, Co S, Paul F, Bellmann-Strobl J, Scheibenbogen C. Chronic COVID-19 syndrome and chronic fatigue syndrome (ME\/CFS) following the first pandemic wave in Germany- a first analysis of a prospective observational study. medRxiv; 2021."},{"key":"7982_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.bbi.2015.09.013","volume":"52","author":"M Loebel","year":"2016","unstructured":"Loebel M, Grabowski P, Heidecke H, Bauer S, Hanitsch LG, Wittke K, et al. Antibodies to beta adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain Behav Immun. 2016;52:32\u20139.","journal-title":"Brain Behav Immun."},{"issue":"7","key":"7982_CR8","doi-asserted-by":"publisher","first-page":"e0129898","DOI":"10.1371\/journal.pone.0129898","volume":"10","author":"O Fluge","year":"2015","unstructured":"Fluge O, Risa K, Lunde S, Alme K, Rekeland IG, Sapkota D, et al. B-lymphocyte depletion in myalgic encephalopathy\/ chronic fatigue syndrome. an open-label phase II study with rituximab maintenance treatment. PLoS One. 2015;10(7):e0129898.","journal-title":"PLoS One."},{"key":"7982_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fmed.2020.00162","volume":"7","author":"IG Rekeland","year":"2020","unstructured":"Rekeland IG, Fossa A, Lande A, Ktoridou-Valen I, Sorland K, Holsen M, et al. Intravenous cyclophosphamide in myalgic encephalomyelitis\/chronic fatigue syndrome. An open-label phase II study. Front Med (Lausanne). 2020;7:162.","journal-title":"Front Med (Lausanne)."},{"key":"7982_CR10","doi-asserted-by":"crossref","unstructured":"Scheibenbogen C, Sotzny F, Hartwig J, Bauer S, Freitag H, Wittke K, et al. Tolerability and efficacy of s.c. IgG self-treatment in ME\/CFS patients with IgG\/IgG subclass deficiency: a proof-of-concept study. J Clin Med. 2021;10(11).","DOI":"10.3390\/jcm10112420"},{"key":"7982_CR11","doi-asserted-by":"crossref","unstructured":"Brownlie H, Speight N. Back to the future? Immunoglobulin therapy for myalgic encephalomyelitis\/chronic fatigue syndrome. Healthcare (Basel). 2021;9(11).","DOI":"10.3390\/healthcare9111546"},{"key":"7982_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bbi.2020.12.022","volume":"93","author":"C Franke","year":"2021","unstructured":"Franke C, Ferse C, Kreye J, Reincke SM, Sanchez-Sendin E, Rocco A, et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun. 2021;93:415\u20139.","journal-title":"Brain Behav Immun."},{"issue":"1","key":"7982_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41380-021-01148-4","volume":"27","author":"SR Bornstein","year":"2022","unstructured":"Bornstein SR, Voit-Bak K, Donate T, Rodionov RN, Gainetdinov RR, Tselmin S, et al. Chronic post-COVID-19 syndrome and chronic fatigue syndrome: is there a role for extracorporeal apheresis? Mol Psychiatry. 2022;27(1):34\u20137.","journal-title":"Mol Psychiatry."},{"key":"7982_CR14","doi-asserted-by":"publisher","first-page":"100100","DOI":"10.1016\/j.jtauto.2021.100100","volume":"4","author":"G Wallukat","year":"2021","unstructured":"Wallukat G, Hohberger B, Wenzel K, Furst J, Schulze-Rothe S, Wallukat A, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100.","journal-title":"J Transl Autoimmun."},{"issue":"9","key":"7982_CR15","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/jnnp-2020-323678","volume":"91","author":"L Delamarre","year":"2020","unstructured":"Delamarre L, Gollion C, Grouteau G, Rousset D, Jimena G, Roustan J, et al. COVID-19-associated acute necrotising encephalopathy successfully treated with steroids and polyvalent immunoglobulin with unusual IgG targeting the cerebral fibre network. J Neurol Neurosurg Psychiatry. 2020;91(9):1004\u20136.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"6","key":"7982_CR16","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1176\/appi.ajp.2020.20081236","volume":"178","author":"J Mulder","year":"2021","unstructured":"Mulder J, Feresiadou A, Fallmar D, Frithiof R, Virhammar J, Rasmusson A, et al. autoimmune encephalitis presenting with malignant catatonia in a 40-year-old male patient with COVID-19. Am J Psychiatry. 2021;178(6):485\u20139.","journal-title":"Am J Psychiatry."},{"issue":"3","key":"7982_CR17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00415-020-10108-x","volume":"268","author":"A Guilmot","year":"2021","unstructured":"Guilmot A, Maldonado Slootjes S, Sellimi A, Bronchain M, Hanseeuw B, Belkhir L, et al. Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. J Neurol. 2021;268(3):751\u20137.","journal-title":"J Neurol."},{"issue":"3","key":"7982_CR18","doi-asserted-by":"publisher","first-page":"e0193672","DOI":"10.1371\/journal.pone.0193672","volume":"13","author":"C Scheibenbogen","year":"2018","unstructured":"Scheibenbogen C, Loebel M, Freitag H, Krueger A, Bauer S, Antelmann M, et al. Immunoadsorption to remove ss2 adrenergic receptor antibodies in chronic fatigue syndrome CFS\/ME. PLoS One. 2018;13(3):e0193672.","journal-title":"PLoS One."},{"key":"7982_CR19","doi-asserted-by":"crossref","unstructured":"Tolle M, Freitag H, Antelmann M, Hartwig J, Schuchardt M, van der Giet M, et al. Myalgic encephalomyelitis\/chronic fatigue syndrome: efficacy of repeat immunoadsorption. J Clin Med. 2020;9(8).","DOI":"10.3390\/jcm9082443"},{"key":"7982_CR20","doi-asserted-by":"crossref","unstructured":"Dorst J, Fillies F, Dreyhaupt J, Senel M, Tumani H. Safety and tolerability of plasma exchange and immunoadsorption in neuroinflammatory diseases. J Clin Med. 2020;9(9).","DOI":"10.3390\/jcm9092874"},{"issue":"1","key":"7982_CR21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/1744-9987.13663","volume":"26","author":"K Fuchs","year":"2022","unstructured":"Fuchs K, Rummler S, Ries W, Helmschrott M, Selbach J, Ernst F, et al. Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications. Ther Apher Dial. 2022;26(1):229\u201341.","journal-title":"Ther Apher Dial."},{"issue":"1","key":"7982_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/jca.21953","volume":"37","author":"SC Boedecker","year":"2022","unstructured":"Boedecker SC, Luessi F, Engel S, Kraus D, Klimpke P, Holtz S, et al. Immunoadsorption and plasma exchange-efficient treatment options for neurological autoimmune diseases. J Clin Apher. 2022;37(1):70\u201381.","journal-title":"J Clin Apher."},{"issue":"1","key":"7982_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jpsychores.2009.10.007","volume":"69","author":"M Cella","year":"2010","unstructured":"Cella M, Chalder T. Measuring fatigue in clinical and community settings. J Psychosom Res. 2010;69(1):17\u201322.","journal-title":"J Psychosom Res."},{"key":"7982_CR24","doi-asserted-by":"crossref","unstructured":"O'Dowd H, Gladwell P, Rogers CA, Hollinghurst S, Gregory A. Cognitive behavioural therapy in chronic fatigue syndrome: a randomised controlled trial of an outpatient group programme. Health Technol Assess. 2006;10(37) iii-iv, ix-x, 1-121.","DOI":"10.3310\/hta10370"},{"key":"7982_CR25","doi-asserted-by":"crossref","unstructured":"Smakowski A, Adamson J, Turner T, Chalder T. Graded exercise therapy for patients with chronic fatigue syndrome in secondary care - a benchmarking study. Disabil Rehabil. 2021;1-9.","DOI":"10.1080\/09638288.2021.1949049"},{"key":"7982_CR26","doi-asserted-by":"crossref","unstructured":"Crawley E, Collin SM, White PD, Rimes K, Sterne JAC, May MT. Treatment outcome in adults with chronic fatigue syndrome: a prospective study in England based on the CFS\/ME National Outcomes Database. QJM. 2020;106.","DOI":"10.1093\/qjmed\/hct122"},{"issue":"5","key":"7982_CR27","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1037\/a0033561","volume":"81","author":"AJ Wearden","year":"2013","unstructured":"Wearden AJ, Emsley R. Mediators of the effects on fatigue of pragmatic rehabilitation for chronic fatigue syndrome. J Consult Clin Psychol. 2013;81(5):831\u20138.","journal-title":"J Consult Clin Psychol."},{"issue":"2","key":"7982_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0022-3999(93)90081-P","volume":"37","author":"T Chalder","year":"1993","unstructured":"Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, et al. Development of a fatigue scale. J Psychosom Res. 1993;37(2):147\u201353.","journal-title":"J Psychosom Res."},{"key":"7982_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12874-016-0167-6","volume":"16","author":"A Nordin","year":"2016","unstructured":"Nordin A, Taft C, Lundgren-Nilsson A, Dencker A. Minimal important differences for fatigue patient reported outcome measures-a systematic review. BMC Med Res Methodol. 2016;16:62.","journal-title":"BMC Med Res Methodol."},{"issue":"9151","key":"7982_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0140-6736(98)04074-4","volume":"353","author":"AJ Cleare","year":"1999","unstructured":"Cleare AJ, Heap E, Malhi GS, Wessely S, O\u2019Keane V, Miell J. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. Lancet. 1999;353(9151):455\u20138.","journal-title":"Lancet."},{"key":"7982_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.981532","volume":"13","author":"F Sotzny","year":"2022","unstructured":"Sotzny F, Filgueiras IS, Kedor C, Freitag H, Wittke K, Bauer S, et al. Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in post COVID syndrome correlate with symptom severity. Front Immunol. 2022;13.","journal-title":"Front Immunol."},{"key":"7982_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bbi.2023.01.006","volume":"109","author":"C Franke","year":"2023","unstructured":"Franke C, Boesl F, Goereci Y, Gerhard A, Schweitzer F, Schroeder M, et al. Association of cerebrospinal fluid brain-binding autoantibodies with cognitive impairment in post-COVID-19 syndrome. Brain Behav Immun. 2023;109:139\u201343.","journal-title":"Brain Behav Immun."},{"issue":"1","key":"7982_CR33","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.1038\/s41467-022-32507-6","volume":"13","author":"C Kedor","year":"2022","unstructured":"Kedor C, Freitag H, Meyer-Arndt L, Wittke K, Hanitsch LG, Zoller T, et al. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. Nat Commun. 2022;13(1):5104.","journal-title":"Nat Commun."},{"issue":"10","key":"7982_CR34","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/alz.12137","volume":"16","author":"M Boada","year":"2020","unstructured":"Boada M, Lopez OL, Olazaran J, Nunez L, Pfeffer M, Paricio M, et al. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer\u2019s disease: primary results of the AMBAR Study. Alzheimers Dement. 2020;16(10):1412\u201325.","journal-title":"Alzheimers Dement."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-07982-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-024-07982-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-07982-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T15:03:28Z","timestamp":1710083008000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-024-07982-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["7982"],"URL":"https:\/\/doi.org\/10.1186\/s13063-024-07982-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"assertion":[{"value":"11 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for the trial was obtained by the Berlin statal ethics committee with reference number 22-735_1-MP Mono \u2013 IV E 17. Written informed consent will be obtained from all patients recording to GCP. All study participants are insured according to the requirements of the German Drug Law.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"172"}}